Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood
Главные авторы: Schuurhuis, Gerrit J., Heuser, Michael, Freeman, Sylvie, Béné, Marie-Christine, Buccisano, Francesco, Cloos, Jacqueline, Grimwade, David, Haferlach, Torsten, Hills, Robert K., Hourigan, Christopher S., Jorgensen, Jeffrey L., Kern, Wolfgang, Lacombe, Francis, Maurillo, Luca, Preudhomme, Claude, van der Reijden, Bert A., Thiede, Christian, Venditti, Adriano, Vyas, Paresh, Wood, Brent L., Walter, Roland B., Döhner, Konstanze, Roboz, Gail J., Ossenkoppele, Gert J.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2018
Предметы:
Special Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5865231/
https://ncbi.nlm.nih.gov/pubmed/29330221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-801498
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы